Aberrancy: electrophysiologic aspects.
D000200:Action Potentials; D000328:Adult; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000209:etiology*; D001919:Bradycardia / Q000209:etiology; D002037:Bundle-Branch Block / Q000150:complications; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D006329:Heart Conduction System; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008564:Membrane Potentials; D008839:Microelectrodes; D009203:Myocardial Infarction / Q000150:complications; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011689:Purkinje Cells / Q000502:physiology; D011802:Quinidine / Q000627:therapeutic use; D012849:Sinoatrial Node; D013610:Tachycardia / Q000209:etiology
D010672:Phenytoin; D011802:Quinidine; D011342:Procainamide